Focus: Eyconis is a newly founded (2024) biotechnology company headquartered in Redwood City, CA, focused on developing novel, best-in-class therapeutics for eye diseases, particularly ophthalmology.
Profile data last refreshed 5h ago · AI intelligence enriched 3w ago
Eyconis is a high-risk, high-optionality opportunity for early-career scientists willing to bet on an unfunded public biotech in a niche ophthalmology space.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Eyconis
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Eyconis's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Eyconis to Participate in Upcoming Investor Conferences - The Manila Times
Eyconis to Participate in Upcoming Investor Conferences The Manila Times
Eyconis initiates first-in-human wet AMD trial on anti-VEGF therapy - Glance by Eyes On Eyecare
Eyconis initiates first-in-human wet AMD trial on anti-VEGF therapy Glance by Eyes On Eyecare
Eyconis Announces Initiation of First-in-Human Clinical - GlobeNewswire
Eyconis Announces Initiation of First-in-Human Clinical GlobeNewswire
Eyconis Doses First Patients in Phase 1b/2a Trial of Long-Acting Anti-VEGF Therapy EYC-0305 for Wet AMD - BioPharm International
Eyconis Doses First Patients in Phase 1b/2a Trial of Long-Acting Anti-VEGF Therapy EYC-0305 for Wet AMD BioPharm International
Ascendis axes IL-2 program in retreat from oncology expansion - Fierce Biotech
Ascendis axes IL-2 program in retreat from oncology expansion Fierce Biotech
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo